Zambia: Encouraging new results further demonstrate effectiveness of the single dose oral cholera vaccine
The results of the study – conducted by Médecins Sans Frontières (MSF), the organisation’s research arm, Epicentre, the Zambian Ministry Of Health (MOH), the Pasteur Institute and the World Health Organization (WHO) - were published in the 8 February edition of The New England Journal of Medicine.
Previous studies have already shown the effectiveness of one dose of oral cholera vaccine, however they were conducted in countries that had recently experienced cholera. At the time of the 2016 outbreak, Zambia had not reported a case of cholera in four years.
“According to these results, people vaccinated can be protected against cholera a few days after receiving one dose,” says Dr. Francisco Luquero, Epicentre. “This is important in outbreaks when we need to protect people quickly. We now know that just one dose provides adequate short term protection both for people with recent exposure to the disease and also for those who have not been exposed to it in several years, such as people in Lusaka and much of sub-Saharan Africa.”
The results for children under five however, are still not clear, as there were few occurrences of the disease in children in the 2016 epidemic. “It is important that future studies look at the effect of the vaccine on children under five, as they are generally less protected and more vulnerable to the disease,” continues Luquero.
In April 2016, the Zambian MOH, supported by MSF and the WHO, implemented an emergency single-dose vaccination campaign in Lusaka. It targeted more than half a million people. A global shortage of vaccines at the time led to the decision to provide one dose only, therefore allowing more people to be protected. The second dose was delivered in 2016 by the MOH, when more vaccines became available.
“While the availability of vaccines has improved in recent years, the number is still far from being sufficient to tackle the large-scale outbreaks we are currently seeing, such as those currently ongoing in the Democratic Republic of Congo, or Yemen.”
“However, we are extremely encouraged by these results which will mean more people can be protected from this potentially deadly disease,” concludes Luquero.